Hyperbaric oxygen therapy dramatically improves Long COVID brain fog, fatigue and cognitive function
Hyperbaric oxygen therapy dramatically improves Long COVID brain fog, fatigue and cognitive function
Understanding Long COVID, post-COVID brain fog and how HBOT addresses the root mechanisms
Long COVID — also called Post-COVID Condition, post-COVID syndrome, or Long Haul COVID — refers to the persistence of symptoms for weeks, months or years after the acute SARS-CoV-2 infection has resolved. Estimates suggest that 10 to 30% of people who contract COVID-19 develop some form of Long COVID, making it one of the largest chronic illness populations created by a single pathogen in modern medical history. In the United States alone, tens of millions of people are affected.
Long COVID presents across a wide spectrum of symptoms and severities. The most common and disabling include profound fatigue, post-exertional malaise (PEM), cognitive impairment and brain fog, shortness of breath, palpitations, sleep disturbances, pain and autonomic dysfunction such as POTS. Brain fog — a cluster of cognitive symptoms including difficulty concentrating, memory impairment, slowed thinking, word-finding difficulties and mental exhaustion — is among the most frequently reported and most functionally limiting features. Many patients describe the cognitive impact of Long COVID as more disabling than the physical fatigue.
The mechanisms driving Long COVID are increasingly well understood. Neuroimaging and autopsy studies have revealed widespread cerebral hypoperfusion, neuroinflammation driven by persistent microglial activation, and evidence of microthrombi in small cerebral vessels. Metabolomics and mitochondrial research has documented impaired cellular energy metabolism. Neuroimmune dysregulation — with chronic activation of pro-inflammatory pathways — perpetuates symptoms long after viral clearance. These overlapping pathologies explain both why Long COVID produces such diverse symptoms and why HBOT — which addresses hypoxia, inflammation, mitochondrial function and vascular repair simultaneously — produces such broad and meaningful improvements.
Our experience at Bay Area Hyperbarics: We have treated dozens of Long COVID patients at our clinic, and each of them has shown remarkable improvement in their symptoms following HBOT. Patients consistently report reductions in brain fog and cognitive difficulty, improved energy and stamina, better sleep, reduced post-exertional malaise and an overall return toward their pre-COVID level of functioning. Many describe HBOT as the first intervention that produced meaningful, lasting change after months or years of struggling with Long COVID symptoms. This clinical experience aligns directly with the findings of the 2022 Efrati randomized controlled trial — the most rigorous clinical evidence published for any Long COVID intervention to date.
Brain fog — difficulty concentrating, memory lapses, slowed thinking and word-finding difficulties
Profound, persistent fatigue not relieved by rest
Post-exertional malaise — worsening of all symptoms after physical or cognitive effort
Shortness of breath and cardiovascular symptoms including palpitations
Sleep disturbances, pain and sensory sensitivities
Autonomic dysfunction — POTS, orthostatic intolerance, blood pressure dysregulation
How HBOT addresses the root causes of Long COVID and brain fog
Long COVID is not one disease — it is a constellation of overlapping pathologies: neuroinflammation, cerebral hypoperfusion, mitochondrial dysfunction, endothelial injury and dysautonomia. HBOT addresses all of these simultaneously, which is why the improvements our patients experience are often broad and transformative.
Restores blood flow to hypoperfused brain regions
Reduces neuroinflammation driving brain fog and cognitive impairment
Improves mitochondrial function and cellular energy production
Reverses cognitive impairment and brain fog
Reduces fatigue and post-exertional malaise
Promotes repair of microvasculature and tissue injury from COVID-19
For Providers
Clinical evidence for HBOT in Long COVID and post-COVID brain fog
HBOT for Long COVID has the most compelling and rapidly growing evidence base of any off-label HBOT application, anchored by a landmark randomized controlled trial published in 2022.
Efrati et al. — landmark randomized controlled trial (2022): The most important study in HBOT for Long COVID was published by Shai Efrati and colleagues at the Sagol Center for Hyperbaric Medicine in Tel Aviv in Scientific Reports (Nature portfolio) in July 2022. This randomized, sham-controlled, double-blind trial enrolled 73 Long COVID patients with persistent cognitive symptoms and randomized them to receive either 40 sessions of HBOT at 2.0 ATA breathing 100% oxygen for 90 minutes, or sham treatment. The HBOT group demonstrated statistically significant improvements in global cognitive function, attention, executive function, information processing speed and memory on objective neuropsychological testing. Crucially, MRI perfusion imaging and SPECT neuroimaging confirmed objective improvements in cerebral blood flow in the HBOT group, providing neuroimaging validation of the cognitive gains. Quality of life, fatigue and sleep also improved significantly. [Zilberman-Itskovich S et al. Sci Rep. 2022;12(1):11110. PMID: 35773271]
Neuroinflammation in Long COVID: Multiple studies using PET imaging have documented elevated neuroinflammatory markers throughout the brains of Long COVID patients, with the most consistent findings in the brainstem, thalamus and prefrontal cortex. Elevated microglial activation in these regions correlates directly with the severity of cognitive symptoms. HBOT's well-documented anti-inflammatory effects — suppressing TNF-α, IL-1β and other pro-inflammatory cytokines and reducing microglial activation — provide a direct mechanistic target for the neuroinflammatory pathology of Long COVID. [Monje M, Iwasaki A. The neurobiology of long COVID. Neuron. 2022;120(6):1116–1131. PMID: 36288726]
Cerebral hypoperfusion in Long COVID: Multiple independent MRI perfusion and SPECT studies have confirmed reduced cerebral blood flow in Long COVID patients, particularly in frontal and parietal regions associated with attention, executive function and working memory. HBOT's ability to increase cerebral oxygen delivery and stimulate angiogenesis in hypoperfused tissue provides a direct mechanism by which it reverses the perfusion deficit underlying Long COVID cognitive impairment.
Mitochondrial dysfunction in Long COVID: Metabolomics and bioenergetic studies have documented widespread mitochondrial dysfunction in Long COVID, including impaired complex I and complex IV activity and reduced ATP production efficiency. This cellular energy deficit directly contributes to the profound fatigue and post-exertional malaise that define Long COVID. HBOT stimulates mitochondrial biogenesis and improves mitochondrial respiratory chain efficiency, providing a mechanistic explanation for the fatigue improvements seen in treated patients. [Guntur VP et al. Metabolism. 2022;128:155112. PMID: 34921860]
Microvascular injury from SARS-CoV-2: Post-mortem and in vivo studies confirm that SARS-CoV-2 directly injures vascular endothelium, causing microthrombi and small vessel occlusion throughout multiple organs including the brain. HBOT stimulates endothelial repair through angiogenesis and CD34+ stem cell mobilization, addressing the microvascular component of Long COVID that contributes to both organ-specific and systemic symptoms.
Efrati fibromyalgia RCT (2015) — mechanistic parallel: In a 2015 PLOS ONE RCT, Efrati and colleagues demonstrated that 40 sessions of HBOT at 2.0 ATA produced statistically significant improvements in pain, fatigue and cognitive symptoms in fibromyalgia patients — a condition with substantial mechanistic overlap with Long COVID — with SPECT neuroimaging showing objective cerebral blood flow improvements. This earlier trial provided the mechanistic foundation and protocol design for the 2022 Long COVID RCT. [Efrati S et al. PLOS ONE. 2015;10(5):e0127012. PMID: 25974026]
Our Long COVID HBOT protocol at Bay Area Hyperbarics
HBOT for Long COVID follows the 40-session protocol validated in the 2022 Efrati randomized controlled trial — the strongest clinical evidence to date for any intervention in Long COVID. Our experience treating dozens of Long COVID patients at Bay Area Hyperbarics reinforces the trial findings: meaningful, often remarkable improvement is achievable.
Comprehensive Long COVID evaluation
Our medical team reviews your COVID history, current symptom burden, cognitive and functional status, and any neuroimaging or neuropsychological testing available. We explain the evidence base for HBOT in Long COVID, discuss what you can realistically expect based on your symptom profile, and design a treatment protocol tailored to your situation.
40-session HBOT course mirroring the clinical trial protocol
The landmark 2022 Efrati RCT used 40 sessions of HBOT at 2.0 ATA breathing 100% oxygen for 90 minutes per session. We follow this evidence-based protocol as our standard Long COVID course. Sessions are administered five days per week over eight weeks, with cognitive and functional assessment at course completion to evaluate your response.
Outcome review and maintenance planning
At the end of your initial course, we review cognitive function, fatigue levels, post-exertional malaise threshold and overall quality of life with you. Many Long COVID patients benefit from maintenance sessions to sustain improvements and continue recovery. We work with you to develop a practical long-term plan.
Frequently Asked Questions
Answers to the questions Long COVID patients most often ask about hyperbaric oxygen therapy.
We have treated dozens of Long COVID patients at Bay Area Hyperbarics, and each of them has shown remarkable improvement in their symptoms. The improvements we see clinically align with what the 2022 Efrati randomized controlled trial demonstrated: meaningful gains in cognitive function, significant reductions in fatigue, improved sleep, better stamina and a reduction in post-exertional malaise. Many of our patients describe HBOT as the first treatment that produced a genuine shift in how they feel after months or years of struggling with Long COVID.
Still suffering from Long COVID? HBOT can help
Bay Area Hyperbarics has treated dozens of Long COVID patients, and each of them has shown remarkable improvement in their symptoms following HBOT. Call us to schedule a consultation and find out how HBOT can help you reclaim your health after COVID-19.
